XOMA to Present At Two Investor Conferences in February
Friday February 9, 12:19 pm ET
BERKELEY, Calif., Feb. 9, 2007 (PRIME NEWSWIRE) -- XOMA Ltd. (NasdaqGM:XOMA - News) announced today that J. David Boyle II, XOMA's vice president of finance and chief financial officer, will present an overview of XOMA's business strategy and an update of the company's pipeline and collaborations at the BIO CEO & Investor Conference on Monday, February 12 at 11:45 a.m. Eastern time at the Waldorf Astoria Hotel in New York, N.Y. Mr. Boyle's presentation will be followed immediately by a breakout question and answer session. Parties interested in scheduling one-on-one meetings are invited to contact Amy Deiner at adeiner@bio.org. An audio webcast of the presentation will be available live on the XOMA website at investors.xoma.com. An archived version of the webcast will be available for 90 days following the presentation.
ADVERTISEMENT
On Monday, February 26, 2007 at 4:00 p.m. Pacific time, Mr. Boyle will present an overview of XOMA's business strategy and an update of the company's pipeline and collaborations at the 3rd Annual Winter Technology & Healthcare Conference hosted by Security Research Associates, Inc. (SRA) at the Omni Hotel, 500 Montgomery St., San Francisco, Calif. Inquiries about conference attendance should be directed to SRA at (415) 925-0264.
About XOMA
XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies, with a therapeutic focus that includes cancer and immune diseases. XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Serono, SA) to treat moderate-to-severe plaque psoriasis, and LUCENTIS(r) (ranibizumab injection), a monoclonal antibody product marketed worldwide (by Genentech and Novartis AG) to treat neovascular (wet) age-related macular degeneration.
The company has built a premier antibody discovery and development platform that includes access to seven of the leading commercially available antibody phage display libraries and XOMA's proprietary Human Engineering(tm) and bacterial cell expression (BCE) technologies. More than 45 companies have signed BCE licenses. XOMA's development collaborators include Lexicon Pharmaceuticals, Inc., Novartis, Schering-Plough Corporation (NYSE:SGP - News) and Takeda Pharmaceutical Company Limited. With a fully integrated product development infrastructure, XOMA's product development capabilities extend from preclinical sciences to product launch. For more information, please visit the company's website at xoma.com. |
